User:Aviwe97/sandbox

Introduction
Red biotechnology (Bio-pharmaceutical) is a process that utilizes organisms to improve health care and help the body to fight diseases. It is a branch of modern biotechnology which is utilized in the field of medicine. Red biotechnology is not only limited to the pharmaceutical industry but also to the medical sector as it facilitates the alleviation of human suffering and enhances the quality of life.It has become tremendous use in clinical research and trials, gene therapy and in diagnostic of the gene. Genetic engineering, production, and development of various medicines to treat different life-threatening diseases, which is a part of the benefits of red biotechnology.

Many branches of medicine in which this technology assumes to have great importance are the production of combination vaccines like Hepatitis B, Hepatitis A, DPT, and polio vaccine that is meant to be injected. This technology is beneficial in the field of poultry farming as well as in tissue engineering. Other areas where red biotechnology is useful are in the fields of cancer research, veterinary, production of biochips and so on. Red biotechnology brings all the biotechnology uses to medicine.

Medicine
In medicine, modern biotechnology has many applications in areas such as pharmaceutical drug discoveries and production, pharmacogenomics, and genetic testing (or genetic screening). Researchers in the field investigate the influence of genetic variation on drug responses in patients by correlating gene expression or single-nucleotide polymorphisms with a drug's efficacy or toxicity.

Genetic testing
Genetic testing allows the genetic diagnosis of vulnerabilities to inherited diseases, and can also be used to determine a child's parentage (genetic mother and father) or in general a person's ancestry. In addition to studying chromosomes to the level of individual genes, genetic testing in a broader sense includes biochemical tests for the possible presence of genetic diseases, or mutant forms of genes associated with increased risk of developing genetic disorders. Genetic testing identifies changes in chromosomes, genes, or proteins.

Market dynamics
The global red biotechnology market is poised to grow at CAGR above 5.6 % over the forecast time frame 2019 to 2026 and reach the market value around USD 500 billion by 2026. Keeping the regulators of biotechnology and pharmaceutical companies in line with standardized legislation is quoted as a key milestone to business development. While the growing incidence of cancer offers a broader range for red biotechnology players in the industry, costly cancer therapeutic technology and machinery are likely to impose economic burdens on patients, which in turn hinder the development of the red biotechnology industry.

It was not unnoticed that a broad range of apps are using artificial intelligence. In the run-up to this, use of biotechnology has gradually begun to revolutionize study operations, as it dramatically minimizes the cost and time engaged in developing life-saving medicines. Biotechnology companies have achieved a competitive advantage with cloud-based technology and AI consequences and have increasingly focused on R&D.

Support sectors, including health service businesses, are continually increasing in the biotech industry. Investors, especially in fields like biotechnology, are brilliantly shining health start-ups. The healthcare industry as a whole has mentioned the fact that investment dollars, greater assessments, and study activities for biopharmaceutical manufacturing will probably remain consistent over the near future.

Market developments
Approval of KANJINTI and Herptin for the treatment of HER2-overe-expressing metastatic gastric or gastroesophageal junction adenocarcinoma and HER2-overexpressing adjuvant and metastatic breast cancer was announced by Amgen and Allergan plc in June 2019 to the US FDA.

Biosimilar anti-TNF information, which covers BENEPALI, FLIXABI, and IMRALDE, have lately been announced by Biogen Inc. The firm estimated that the use of its biosimilars in Europe saved almost 2 billion euros in healthcare costs in 2019. In the first place, it has received 145.000 biogenic treatments in Europe. In a recent Australian Research and Development briefing CSL Limited highlighted advances in cell-based vaccine technology. Actual information and emerging evidence suggest that, compared to conventional egg-based vaccine, cell-based influenza vaccines can provide better influenza-related results.